Lessard Frédéric, Saint-Germain Emmanuelle, Mignacca Lian, Ferbeyre Gerardo
Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, Québec, Canada.
CRCHUM, Montréal, Québec, Canada.
Oncoscience. 2019 Dec 23;6(11-12):386-389. doi: 10.18632/oncoscience.495. eCollection 2019 Nov.
Suppressor of cytokine signaling (SOCS) family members are upregulated following JAK-STAT pathway activation by cytokines. SOCS proteins are recognized inhibitors of cytokine signaling playing roles in cell growth and differentiation. Moreover, SOCS1 and SOCS3 have been shown to be involved in tumor suppression through their ability to interact with p53 leading to the activation of its transcriptional program and showing the implication of SOCS family members in the regulation of apoptosis, ferroptosis and senescence. More recently, we demonstrated that the SRC family of non-receptor tyrosine kinases (SFK) can phosphorylate SOCS1 leading to its homodimerization and inhibiting its interaction with p53. Then, we reactivated the SOCS1-p53 tumor suppressor axis with the SFK inhibitor dasatinib in combination with the p53 activating compound PRIMA. This work suggests new avenues for cancer treatment and leaves open several new questions that deserve to be addressed.
细胞因子信号转导抑制因子(SOCS)家族成员在细胞因子激活JAK-STAT信号通路后会上调。SOCS蛋白是公认的细胞因子信号转导抑制剂,在细胞生长和分化中发挥作用。此外,SOCS1和SOCS3已被证明通过与p53相互作用来抑制肿瘤,从而激活其转录程序,并表明SOCS家族成员参与细胞凋亡、铁死亡和衰老的调节。最近,我们证明非受体酪氨酸激酶(SFK)的SRC家族可以磷酸化SOCS1,导致其同源二聚化并抑制其与p53的相互作用。然后,我们用SFK抑制剂达沙替尼联合p53激活化合物PRIMA重新激活了SOCS1-p53肿瘤抑制轴。这项工作为癌症治疗提出了新的途径,并留下了几个值得解决的新问题。